Regeneron’s Gene Silencing Study Targets Chronic Liver Disease

Regeneron Pharmaceuticals ((REGN)) announced an update on their ongoing clinical study.

Regeneron Pharmaceuticals is conducting a Phase 2 clinical study titled A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors. The study aims to evaluate the effectiveness of the investigational drug ALN-HSD in reducing liver scarring associated with MASH, a chronic liver disease that can lead to severe complications like cirrhosis and liver failure.

The intervention being tested is ALN-HSD, a drug administered via subcutaneous injection, designed to improve liver function and reduce inflammation caused by MASH. The study also seeks to understand the drug’s side effects and its presence in the bloodstream over time.

This study employs a randomized, double-blind, placebo-controlled design with a parallel intervention model. Participants, care providers, investigators, and outcomes assessors are all blinded to the treatment assignments. The primary purpose of the study is treatment-focused.

The study began on February 9, 2023, with an estimated primary completion date in 2025. The last update to the study was submitted on June 23, 2025. These dates are crucial for tracking the study’s progress and anticipating when results might be available.

The market implications of this study could be significant for Regeneron Pharmaceuticals, potentially boosting its stock performance if the results are positive. The study’s focus on a chronic liver disease with limited treatment options could also influence investor sentiment positively. Competitors in the liver disease treatment space will likely monitor these developments closely.

The study is ongoing, with further details available on the ClinicalTrials portal.